PDL Biopharma, formerly known as Protein Design labs, is headquartered in Nevada. The company focuses its efforts in the management of humanized antibody patents and royalty assets. This has enabled the company to drive the discovery of a new generation of cancer and immunological targeted treatments.
The main objectives of this company is to offer debt, royalty financing solutions to private and public healthcare companies developing technologies in Biotech, Pharma, Medtech and Diagnostics. They also provide financial support to academic institutions receiving royalties and assist inventors in diversifying their portfolio. In cases where the counter party does not having a royalty, PDL Biopharma assists to create a synthetic royalty interest which can then be monetized.
The following figure is a partnering list of deals by deal type entered by PDL Biopharma in the last five years
Figure 1: PDL Biopharma partnering deals by deal type 2009-2014
Source: Current Agreements, 2014
The figure above shows the number of licensing and settlement agreements that the company has entered into with biopharma companies for monoclonal antibody technology. This showcases the company’s strategy to invest in new income generating assets and companies.
PDL Biopharma mainly focuses on investment deals offering companies with growth capital and financing solutions that may aid in their technological improvements. The table below shows the type of financing that PDL Biopharma has invested in the last five years.
Figure 2: PDL Biopharma financial investment deals 2009-2014
Source: Current Agreements, 2014
PDL Biopharma offered debt financing to companies like Kaleo, Durata Therapeutics, Paradigm Spine, Merus Lab International and provided royalty and revenue financing to AxoGen, Depomed in the last five years.
The following table provides a summary table of the financing investment deals entered into by PDL Biopharma .
Figure 3: PDL Biopharma financial investment deals by deal value 2009-2014
Source: Current Agreements, 2014
Our report provides more detailed insight into the type of financial investment entered into by PDL Biopharma. See: Partnering Agreements with PDL Biopharma 2009-2014
More
Summary profile for PDL Biopharma
Partnering interests for PDL Biopharma
No M&A deals recorded for PDL Biopharma since 2009
Available reports from Current Partnering
Report: Partnering Agreements with PDL Biopharma 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for PDL Biopharma
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on PDL Biopharma company profile, recent partnering, M&A and financing news and articles
Related
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter